SAGE vs. AXSM, IMGN, BHC, RETA, ZLAB, FOLD, GLPG, MRVI, SDGR, and RVNC
Should you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Axsome Therapeutics (AXSM), ImmunoGen (IMGN), Bausch Health Companies (BHC), Reata Pharmaceuticals (RETA), Zai Lab (ZLAB), Amicus Therapeutics (FOLD), Galapagos (GLPG), Maravai LifeSciences (MRVI), Schrödinger (SDGR), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Sage Therapeutics vs.
Axsome Therapeutics (NASDAQ:AXSM) and Sage Therapeutics (NASDAQ:SAGE) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.
Axsome Therapeutics has higher revenue and earnings than Sage Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
Sage Therapeutics received 231 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 71.73% of users gave Sage Therapeutics an outperform vote while only 67.60% of users gave Axsome Therapeutics an outperform vote.
Axsome Therapeutics currently has a consensus price target of $105.57, suggesting a potential upside of 51.25%. Sage Therapeutics has a consensus price target of $51.54, suggesting a potential upside of 2.60%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Sage Therapeutics.
59.7% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 85.6% of Sage Therapeutics shares are held by institutional investors. 24.5% of Axsome Therapeutics shares are held by insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Axsome Therapeutics had 2 more articles in the media than Sage Therapeutics. MarketBeat recorded 12 mentions for Axsome Therapeutics and 10 mentions for Sage Therapeutics. Sage Therapeutics' average media sentiment score of 0.48 beat Axsome Therapeutics' score of 0.18 indicating that Sage Therapeutics is being referred to more favorably in the news media.
Axsome Therapeutics has a net margin of -109.75% compared to Sage Therapeutics' net margin of -5,932.09%. Sage Therapeutics' return on equity of -42.32% beat Axsome Therapeutics' return on equity.
Axsome Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Summary
Axsome Therapeutics beats Sage Therapeutics on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sage Therapeutics Competitors List
Related Companies and Tools